Pharmaceutical

XtalPi’s AI biologics discovery platform licensed to Janssen Biotech

XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics development.

Oct 12, 2024 - 04:00
XtalPi’s AI biologics discovery platform licensed to Janssen Biotech
XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics development.
Read the original article

Tags:

Previous Article

Roche wins first-line approval for PI3K inhibitor combo in breast cancer

Next Article

Activist investor Starboard cries foul play in exec U-turn at Pfizer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bayer wins FDA breakthrough therapy designation for NSCLC candidate

Bayer wins FDA breakthrough therapy designation for NSC...

Feb 26, 2024

Eli Lilly doubles down on Oblique partnership for antibody generation

Eli Lilly doubles down on Oblique partnership for antib...

Aug 25, 2024

Harnessing the untapped potential of medicines access 

Harnessing the untapped potential of medicines access 

Jan 25, 2024